Share-based Payment Arrangement, Expense of Q32 Bio Inc. from 31 Mar 2017 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Q32 Bio Inc. quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 31 Mar 2017 to 30 Sep 2025.
  • Q32 Bio Inc. Share-based Payment Arrangement, Expense for the quarter ending 30 Sep 2025 was $1,176,000, a 15% decline year-over-year.
  • Q32 Bio Inc. Share-based Payment Arrangement, Expense for the twelve months ending 30 Sep 2025 was $5,037,000, a 38% increase year-over-year.
  • Q32 Bio Inc. annual Share-based Payment Arrangement, Expense for 2024 was $4,386,000, a 207% increase from 2023.
  • Q32 Bio Inc. annual Share-based Payment Arrangement, Expense for 2023 was $1,428,000, a 89% decline from 2022.
  • Q32 Bio Inc. annual Share-based Payment Arrangement, Expense for 2022 was $13,054,000, a 24% decline from 2021.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

Q32 Bio Inc. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $5,037,000 $1,176,000 -$206,000 -15% 01 Jul 2025 30 Sep 2025 10-Q 13 Nov 2025 2025 Q3
Q2 2025 $5,243,000 $1,268,000 -$68,000 -5.1% 01 Apr 2025 30 Jun 2025 10-Q 06 Aug 2025 2025 Q2
Q1 2025 $5,311,000 $1,342,000 +$925,000 +222% 01 Jan 2025 31 Mar 2025 10-Q 08 May 2025 2025 Q1
Q4 2024 $4,386,000 $1,251,000 +$730,000 +140% 01 Oct 2024 31 Dec 2024 10-K 11 Mar 2025 2024 FY
Q3 2024 $3,656,000 $1,382,000 +$1,081,000 +359% 01 Jul 2024 30 Sep 2024 10-Q 13 Nov 2025 2025 Q3
Q2 2024 $2,575,000 $1,336,000 +$1,026,000 +331% 01 Apr 2024 30 Jun 2024 10-Q 06 Aug 2025 2025 Q2
Q1 2024 $1,549,000 $417,000 +$121,000 +41% 01 Jan 2024 31 Mar 2024 10-Q 08 May 2025 2025 Q1
Q4 2023 $1,428,000 $521,000 -$2,568,000 -83% 01 Oct 2023 31 Dec 2023 10-K 11 Mar 2025 2024 FY
Q3 2023 $3,996,000 $301,000 -$2,470,000 -89% 01 Jul 2023 30 Sep 2023 10-Q 07 Nov 2024 2024 Q3
Q2 2023 $6,466,000 $310,000 -$2,833,000 -90% 01 Apr 2023 30 Jun 2023 10-Q 08 Aug 2024 2024 Q2
Q1 2023 $9,299,000 $296,000 -$3,755,000 -93% 01 Jan 2023 31 Mar 2023 10-Q 09 May 2024 2024 Q1
Q4 2022 $13,054,000 $3,089,000 -$1,574,000 -34% 01 Oct 2022 31 Dec 2022 10-K 13 Mar 2024 2023 FY
Q3 2022 $14,628,000 $2,771,000 -$1,455,000 -34% 01 Jul 2022 30 Sep 2022 10-Q 14 Nov 2023 2023 Q3
Q2 2022 $16,083,000 $3,143,000 -$1,330,000 -30% 01 Apr 2022 30 Jun 2022 10-Q 14 Aug 2023 2023 Q2
Q1 2022 $17,413,000 $4,051,000 +$168,000 +4.3% 01 Jan 2022 31 Mar 2022 10-Q 11 May 2023 2023 Q1
Q4 2021 $17,245,000 $4,663,000 +$1,096,000 +31% 01 Oct 2021 31 Dec 2021 10-K 09 Mar 2023 2022 FY
Q3 2021 $16,149,000 $4,226,000 +$880,000 +26% 01 Jul 2021 30 Sep 2021 10-Q 10 Nov 2022 2022 Q3
Q2 2021 $15,269,000 $4,473,000 +$1,021,000 +30% 01 Apr 2021 30 Jun 2021 10-Q 15 Aug 2022 2022 Q2
Q1 2021 $14,248,000 $3,883,000 +$1,000,000 +35% 01 Jan 2021 31 Mar 2021 10-Q 16 May 2022 2022 Q1
Q4 2020 $13,248,000 $3,567,000 +$1,131,000 +46% 01 Oct 2020 31 Dec 2020 10-K 23 Mar 2022 2021 FY
Q3 2020 $12,117,000 $3,346,000 +$1,359,000 +68% 01 Jul 2020 30 Sep 2020 10-Q 15 Nov 2021 2021 Q3
Q2 2020 $10,758,000 $3,452,000 +$1,483,000 +75% 01 Apr 2020 30 Jun 2020 10-Q 12 Aug 2021 2021 Q2
Q1 2020 $9,275,000 $2,883,000 +$1,640,000 +132% 01 Jan 2020 31 Mar 2020 10-Q 06 May 2021 2021 Q1
Q4 2019 $7,635,000 $2,436,000 +$1,481,000 +155% 01 Oct 2019 31 Dec 2019 10-K 11 Mar 2021 2020 FY
Q3 2019 $6,154,000 $1,987,000 +$1,268,000 +176% 01 Jul 2019 30 Sep 2019 10-Q 09 Nov 2020 2020 Q3
Q2 2019 $4,886,000 $1,969,000 +$1,400,000 +246% 01 Apr 2019 30 Jun 2019 10-Q 10 Aug 2020 2020 Q2
Q1 2019 $3,486,000 $1,243,000 +$863,000 +227% 01 Jan 2019 31 Mar 2019 10-Q 07 May 2020 2020 Q1
Q4 2018 $2,623,000 $955,000 +$815,142 +583% 01 Oct 2018 31 Dec 2018 10-K 12 Mar 2020 2019 FY
Q3 2018 $1,807,858 $719,000 +$661,116 +1142% 01 Jul 2018 30 Sep 2018 10-Q 12 Nov 2019 2019 Q3
Q2 2018 $1,146,742 $569,000 +$538,422 +1761% 01 Apr 2018 30 Jun 2018 10-Q 08 Aug 2019 2019 Q2
Q1 2018 $608,320 $380,000 +$352,320 +1273% 01 Jan 2018 31 Mar 2018 10-Q 13 May 2019 2019 Q1
Q4 2017 $256,000 $139,858 01 Oct 2017 31 Dec 2017 10-K 12 Mar 2019 2018 FY
Q3 2017 $57,884 01 Jul 2017 30 Sep 2017 10-Q 13 Nov 2018 2018 Q3
Q2 2017 $30,578 01 Apr 2017 30 Jun 2017 10-Q 13 Aug 2018 2018 Q2
Q1 2017 $27,680 01 Jan 2017 31 Mar 2017 10-Q 14 May 2018 2018 Q1

Q32 Bio Inc. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $4,386,000 +$2,958,000 +207% 01 Jan 2024 31 Dec 2024 10-K 11 Mar 2025 2024 FY
2023 $1,428,000 -$11,626,000 -89% 01 Jan 2023 31 Dec 2023 10-K 11 Mar 2025 2024 FY
2022 $13,054,000 -$4,191,000 -24% 01 Jan 2022 31 Dec 2022 10-K 13 Mar 2024 2023 FY
2021 $17,245,000 +$3,997,000 +30% 01 Jan 2021 31 Dec 2021 10-K 09 Mar 2023 2022 FY
2020 $13,248,000 +$5,613,000 +74% 01 Jan 2020 31 Dec 2020 10-K 23 Mar 2022 2021 FY
2019 $7,635,000 +$5,012,000 +191% 01 Jan 2019 31 Dec 2019 10-K 11 Mar 2021 2020 FY
2018 $2,623,000 +$2,367,000 +925% 01 Jan 2018 31 Dec 2018 10-K 12 Mar 2020 2019 FY
2017 $256,000 01 Jan 2017 31 Dec 2017 10-K 12 Mar 2019 2018 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.